JULY 2016 TABLE OF CONTENTS INTRODUCTION

First Page		Document Content
Date: 2016-07-28 12:58:50 Immunosuppressants Monoclonal antibodies Immunology Biotechnology Immune system TNF inhibitor Infliximab Tocilizumab Adalimumab Tumor necrosis factor alpha Natalizumab Etanercept		JULY 2016 TABLE OF CONTENTS INTRODUCTION Add to Reading List Source URL: www.abirisk.eu Download Document from Source Website File Size: 1,18 MB Share Document on Facebook

	Biotechnology, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xTqy - View Document
	PDF Document DocID: 1wroO - View Document
	Building A Better Mousetrap: Patenting Biotechnology In The European Community DocID: 1vr7C - View Document
	BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod DocID: 1vq6b - View Document
	Biotechnology Consultation Agency Response Letter BNF DocID: 1vpUZ - View Document